$ATTBF Research Issues Research Report

A bird’s eye view of the Company reveals a holding company that aggregates, incubates, develops, and integrates complementary late venture stage entities and their offerings into autonomous yet related divisions. Management has set the stage for Abattis to enjoy substantial revenue growth via a multi-pronged revenue generation approach, including IP Licensing. This strategy includes initially building sales in traditional specialty markets with its broad line of conventional health and wellness products followed by the hockey-stick type growth associated with the cannabis space in North America.

In the research report, analyst Rob Goldman discusses the Company’s unique market positioning, and enviable growth prospects.

Goldman noted, “With sales commencing in 3Q16, Abattis is transforming itself from an R&D entity into a well-positioned revenue-generating company that is an emerging player in the multi-billion dollar nutraceutical and functional foods markets. In the near term, ATTBF is on track to offer a variety of innovative products based on its proprietary Health Canada approved formulations and its portfolio of licensed Natural Product Number (NPN) ingredients which are proven to offer health benefits to consumers. ATTBF plans to offer future products containing cannabinoid ingredients which many medical practitioners believe can help treat a variety of ailments.”

“In the next revenue stage, which could generate hockey-stick type growth, the NVL unit promises to emerge as a premier and rare analytical testing lab, as well as an R&D partner to the legal medical cannabis industry in Canada when commercial operations commence in 2H16. NVL has applied for a Controlled Substance License with Health Canada for the possession of cannabis, and extracts production analysis. Its CSL is pending with final site inspections completed in June 2016. Potentially serving as one of an elite few to perform tests on cannabis ingredients on behalf of production companies is a huge advantage for this emerging entity,” Goldman further commented.

Goldman believes that ATTBF boasts an enviable leadership team with deep marketing experience. “With no long term debt and an improved balance sheet and capital structure, ATTBF is primed to enjoy substantial sales growth. Leveraging its multi-pronged approach and exposure to fast-growing multi-billion dollar markets, we believe ATTBF’s market value is significantly undervalued with a major re-valuation set to occur this year, based in part on the Company’s standing vis-à-vis a key comparable.”

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored research report on Abattis Bioceuticals Corp. which carries a rating and a price target. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Abattis Bioceuticals Corp. (“the Company”) authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission https://www.sec.gov.

Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, article, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download this sponsored research report or any of our research, view our disclosures and disclaimers, or for more information, visitwww.goldmanresearch.com. Goldman Small Cap Research has been compensated by the Company in the amount of $6000 for a research subscription service.

About Abattis Bioceuticals Corp.: Abattis Bioceuticals Corp. (OTCQB – ATTBF) is a specialty biotechnology company that aggregates, incubates, integrates, and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions, and ingredients for the nutraceutical, bioceutical, and functional foods markets. Current product development strategy is focused on high-quality conventional botanical products. Future product development is expected to include new products containing cannabinoid compounds.

Learn more about ATTBF at www.Abattis.com

Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com